G6PD and small cell lung carcinoma: First, patients with SCLC from the cBioPortal platform were divided into G6PDhigh and G6PDlow groups according to the mRNA level of G6PD, and an obvious difference in overall survival was detected between the two groups, but patients in the G6PDlow group had significantly worse clinical outcomes, which seems to differ from our hypothesis.